Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing
Open Access
- 6 January 2019
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 11
Abstract
Background: With increasing numbers of oncology biosimilars in the approval pipeline, it is important to investigate oncology clinicians’ understanding of biosimilars and what information they need prior to adoption. Methods: Between January and May 2018, 77 oncology clinicians (52 physicians, 16 pharmacists, and 9 advanced practice providers) completed a survey covering three domains: clinician understanding, prescription preferences, and patient involvement. An in-depth interview was designed based on themes identified in the first 50 surveys: cost, safety and efficacy, patient preference, and disease stage. Participants were chosen to participate in the interview based on outlying responses to survey questions. Results: When asked to define a biosimilar, 74% (57/77) of respondents could not give a satisfactory definition, and 40.3% (31/77) considered a biosimilar the same as a generic drug. The most important factor in biosimilar prescription was safety and efficacy (4.51 out of 5) followed closely by cost differences (4.34 out of 5). A 40% increase (53.2–94.8%) in clinicians’ prescribing likelihood was seen after a biosimilar is designated as interchangeable. Participants in this study were split regarding the importance of shared decision-making with patients [50.7% (39/77) important or extremely important, 39.0% (30/77) somewhat or not at all important]. Clinicians were also split concerning the role that pharmacists should play in the decision to prescribe or substitute biosimilars. Conclusion: Understanding of biosimilars is low, and educational needs are high. The information that clinicians deem important to assess, such as safety, efficacy and cost, will need to be provided before they are comfortable prescribing biosimilars.Keywords
Funding Information
- National Cancer Institute (P30CA138292)
This publication has 16 references indexed in Scilit:
- Obstacles to the Adoption of Biosimilars for Chronic DiseasesJAMA, 2017
- Medical specialists' attitudes to prescribing biosimilarsPharmacoepidemiology and Drug Safety, 2017
- Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty PhysiciansAdvances in Therapy, 2016
- The Future of Biosimilar InsulinsDiabetes Spectrum, 2016
- Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn’s and Ulcerative Colitis Associations: Table 1.Journal of Crohn's and Colitis, 2016
- Patient attitudes and understanding about biosimilars: an international cross-sectional surveyPatient Preference and Adherence, 2016
- Supplemental effects of mixed ingredients and rice bran on the growth performance, survival and yield of Nile tilapia, Oreochromis niloticus reared in fertilized earthen pondsSpringerPlus, 2016
- Biosimilars: The Need, The Challenge, The Future: The FDA PerspectiveAmerican Journal of Gastroenterology, 2014
- NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety PerspectivesJournal of the National Comprehensive Cancer Network, 2011
- How Many Interviews Are Enough?Field Methods, 2006